Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jul 17;49(1):11-13.
doi: 10.1016/j.immuni.2018.07.001.

A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion

Brendan Horton  1 , Stefani Spranger  2
Affiliations
Comment

A Tumor Cell-Intrinsic Yin-Yang Determining Immune Evasion

Brendan Horton et al. Immunity. .

Abstract

Pancreatic adenocarcinoma (PDAC) is mostly refractory to immunotherapies. In this issue of Immunity, Li et al. (2018) generate a library of clonal PDAC tumors to examine the tumor-intrinsic features shaping the anti-tumor immune response and find that tumor cell-derived CXCL1 directly blunts T cell infiltration and reduces responsiveness to immunotherapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. The Chemokine Yin-Yang Mediating T-Cell-Inflamed and Non-T-Cell-Inflamed Tumors
A heterogeneous tumor cell population comprises both tumor cell clones capable of producing myeloid-attracting chemokines (predominantly blue) and T-cell-attracting chemokines (predominantly red). Based on the expression level of both chemokine groups, the cancer cells will mediate a T-cell-inflamed (red) and non-T-cell-inflamed tumors (blue).
See this image and copyright information in PMC

Comment on

  • Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.
    Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ. Li J, et al. Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26. Immunity. 2018. PMID: 29958801 Free PMC article.

References

    1. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gutgemann I, Eilers M, and Felsher DW (2016). MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352, 227–231. - PMC - PubMed
    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al.; KEYNOTE-189 Investigators (2018). Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 378, 2078–2092. - PubMed
    1. Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, et al. (2016). STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 76, 999–1008. - PMC - PubMed
    1. Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, et al. (2018). Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49, this issue, 178–193. - PMC - PubMed
    1. Moriyama S, Putzel GG, Rakhilin N, et al. (2017). The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation. Nature 549, 282–286. - PMC - PubMed

Substances